HWM
CRSP icon

Howard Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Howard Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-67
Closed -$4K – 183
2019
Q4 		$4K Buy
+67
New +$3.66K ﹤0.01% 416

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Howard Wealth Management's CRSP Position: Q1 2020 in Review

Howard Wealth Management sold out of CRISPR Therapeutics (CRSP) in Q1 2020, closing a stake of 67 shares — an estimated $4K sold.

Howard Wealth Management first reported a position in CRSP in Q4 2019 and held it in 1 quarter. The position peaked at $4K in Q4 2019. 257 funds tracked by Wall St. Rank hold CRSP as of Q1 2020.

  • Howard Wealth Management reported no remaining CRISPR Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Howard Wealth Management sold 67 CRISPR Therapeutics shares in Q1 2020, an estimated $4K.
  • Howard Wealth Management first reported a position in CRISPR Therapeutics in Q4 2019 and held it in 1 quarter.
  • Howard Wealth Management's CRISPR Therapeutics position peaked at $4K in Q4 2019.
  • 257 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2020.

Based on Howard Wealth Management's 13F filing for Q1 2020, filed 4 May 2020.